|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2000-8-15
|
|
pubmed:abstractText |
Weekly administration of docetaxel was found to reduce myelosuppression and other nonhematologic toxicities when compared with administration every 3 weeks. In the current Phase II trial, the authors evaluated the feasibility, toxicity, and efficacy of weekly docetaxel in the treatment of elderly patients with newly diagnosed advanced nonsmall cell lung carcinoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2000 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
89
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
328-33
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10918162-Aged,
pubmed-meshheading:10918162-Aged, 80 and over,
pubmed-meshheading:10918162-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:10918162-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:10918162-Drug Administration Schedule,
pubmed-meshheading:10918162-Female,
pubmed-meshheading:10918162-Humans,
pubmed-meshheading:10918162-Infusions, Intravenous,
pubmed-meshheading:10918162-Lung Neoplasms,
pubmed-meshheading:10918162-Male,
pubmed-meshheading:10918162-Paclitaxel,
pubmed-meshheading:10918162-Survival Analysis,
pubmed-meshheading:10918162-Taxoids
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial.
|
|
pubmed:affiliation |
Sarah Cannon Cancer Center, Nashville, Tennessee 37203, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
